Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

3 Horrendous Health-Care Stocks This Week: Accuray Incorporated (ARAY), Keryx Biopharmaceuticals (KERX)

Page 1 of 2

Baltimore won. Beyonce rocked. But some health-care stocks didn’t have such great experiences. Here are three of the most horrendous performers for the past week.

A beat-down
OraSure Technologies, Inc.
(NASDAQ:OSUR) announced its fourth-quarter results after the market closed on Wednesday. The oral fluid diagnostics maker beat analyst expectations by $0.03 per share. That’s good, right? Maybe so, but it wasn’t good enough. Shares fell by 12% for the week.

The company beat analyst expectations by losing less money than anticipated — $0.11 per share compared to an expected $0.14 per share. Sales declined to $22.1 million but exceeded analyst expectations of $20.9 million. The last quarter’s performance wasn’t the issue, though. Next quarter is a different story.

OraSure projects that first quarter 2013 revenue will be between $20 million and $21 million. The company expects a net loss for the quarter of $0.18-$0.19 per share. Analysts targeted better performance, with the average expectation for revenue of $21.5 million and for a loss of only $0.15 per share.

Accuray Incorporated (NASDAQ:ARAY)

Deja vu?
Like OraSure, shares of Accuray Incorporated (NASDAQ:ARAY) fell by 12% this week. And, again like OraSure, the company beat analyst expectations by losing less money than expected. Feeling a sense of deja vu yet? So far, Accuray’s story sounds a lot like OraSure’s.

Accuray reported revenue for last quarter of $77.8 million. That beat average analyst expectations of $74.2 million but was a drop of 27% year-over-year. The radiation oncology company’s net loss was $0.30 per share. Analysts expected a loss of $0.33 per share.

The company had already provided full-year revenue guidance in line with analyst views. So with this guidance and beats on the top and bottom lines, why did Accuray’s shares tank? It’s probably because of the bleak overall outlook. Accuray recently announced a restructuring to reduce operating costs by $40 million per year. The company also revealed this week that it planned to take on another $75 million in debt.

What goes up…
It was bound to happen sooner or later. After skyrocketing on good news about phase 3 results for Zerenex, shares of Keryx Biopharmaceuticals (NASDAQ:KERX) sank over 10% this week. This drop comes on the heels of a 22% decline last Friday.

Investors are worried about exclusivity for Zerenex after a report came out last week from  IPD Analytics. The research firm warned that Keryx might not be granted New Chemical Entity status by the FDA for Zerenex. IPD also expressed concern that the patents for the drug won’t be strong enough to hold off generic challengers.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!